Understand the source comparison
VIP Dosage Protocol Guide: Peptide Comparison
VIP (Vasoactive Intestinal Peptide) 1.5–2.5 minutes 100–250 mcg per dose Twice daily (BID) VPAC1, VPAC2 (G-protein coupled) Requires structured titration due to rapid metabolism and receptor downregulation risk. Single daily dosing fails mechanistically BPC-15
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- VIP (Vasoactive Intestinal Peptide)
- 1.5–2.5 minutes
- 100–250 mcg per dose
- Twice daily (BID)
- VPAC1, VPAC2 (G-protein coupled)
- Requires structured titration due to rapid metabolism and receptor downregulation risk. Single daily dosing fails mechanistically
- BPC-157
- 4–6 hours
- 250–500 mcg per dose
- Once or twice daily
- Not fully characterised (likely growth factor pathways)
- Longer half-life allows once-daily dosing; less sensitive to timing precision than VIP
- Thymosin Alpha-1
- 2–3 hours
- 1.6–3.2 mg per dose
- Twice weekly
- TLR (Toll-like receptors), immune signalling pathways
- Dosed less frequently due to immune cascade duration; not comparable to VIP's rapid turnover
- Selank
- 30–60 minutes
- BDNF upregulation, GABAergic modulation
- Short half-life but slower receptor adaptation curve than VIP. Less titration-sensitive
- Cerebrolysin
- 3–6 hours (complex mixture)
- 5–10 mL per dose
- 5 days per week (research standard)
- Neurotrophic factor receptors
- Injectable neuropeptide blend requiring less frequent dosing than VIP due to sustained neuroplastic effects